Physician profile
David J Hoopes
NPI 1962520080
$6,347.72
in general payments reported to CMS, 2019-2025
66 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $190 · 2021: $774 · 2022: $1,541 · 2023: $1,914 · 2024: $1,412 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $473.89 | 2021-2024 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $455.28 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $390.78 | 2021-2025 | Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $384.67 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $304.44 | 2020-2025 | Ultomiris |
| Daiichi Sankyo INC. | $261.65 | 2021-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $241.48 | 2021-2023 | Imbruvica |
| Coherus Oncology, INC. | $220.40 | 2020-2023 | |
| Pfizer INC. | $206.20 | 2021-2025 | |
| Incyte Corporation | $204.73 | 2021-2025 | Jakafi |
| Beigene USA, INC. | $193.93 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $174.98 | 2023-2024 | Libtayo |
| Seagen INC. | $158.43 | 2019-2023 | Adcetris, Tivdak |
| Puma Biotechnology, INC. | $156.34 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $144.19 | 2019-2024 | Onivyde, Somatuline Depot, Tazverik |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hoopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.